β Amyloid (1-14), human

Cat. No.: HY-P10628: FAQs
Data Sheet Handling Instructions

Molarity Calculator

β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research.

For research use only. We do not sell to patients.

β Amyloid (1-14), human Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research^[1].
Molecular Weight	1697.72
Formula	C₇₃H₁₀₀N₂₄O₂₄
Sequence	Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-NH2
Sequence Shortening	DAEFRHDSGYEVHH-NH2
SMILES	O=C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC2=CNC=N2)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(NCC(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC4=CNC=N4)C(N[C@@H](CC5=CNC=N5)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(O)=O)N
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (258 KB) Handling Instructions (2659 KB)
References	[1]. Hifumi, et al. "New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of β‐amyloid molecule along with the peptidase activity." FASEB bioAdvances 1.2 (2019): 93. [Content Brief]